GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2012

Funding for Stem Cell Treatment of Compartment Syndrome

  • America Stem Cell (ASC) won an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute (NHLBI) to evaluate the use of its ASC-101 stem technology in combination with the Wake Forest Institute of Regenerative Medicine’s (WFIRM) amniotic fluid-derived stem cells in an experimental model of compartment syndrome. The condition can arise following a range of injuries including fractures, burns, trauma, post-ischemic swelling, and gunshot wounds, leading to loss of muscle tissue.

    ASC-101 is a human recombinant enzyme technology designed to increase the efficiency of engraftment of cord blood-derived stem cell transplants, and enhance the ability of other types of stem cell to home in on their target tissues. A number of collaborations are in place to evaluate the potential to use ASC-101 for improving cell therapies for multiple conditions using a range of cell types. Initial clinical trials with ASC-101 are ongoing in hematopoietic stem cell transplantation.

    The firm says the STTR grant will allow it to evaluate combining its technology with amniotic fluid-derived stem cells. “The combination of ASC-101 with amniotic fluid-derived stem cells could synergistically enhance the therapeutic and regenerative capacity of these cells and most importantly provide an off-the-shelf, effective solution for tissue damage due to multiple types of injuries or diseases,” remarks Lynnet Koh, ASC’s CEO.“


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?